ALGN: Align Technology, Inc. $173.18
52-wk High $208.31
📌 Investment Snapshot
- 💰 Price & Valuation: ALGN trades at $173.18 with a 30.7x P/E, a premium to the S&P 500 average.
- 📈 Latest Quarter: Q4 FY25 revenue was $1.0B, marking a +5.3% YoY increase.
- 🔑 Key Catalyst: Continued adoption of Invisalign and expansion into new markets remain core growth drivers.
- 🎯 Consensus: BUY rating from 13 analysts, with a mean target of $202, implying +16.6% upside.
Align Technology’s current price of $173.18 sits below its 50-day SMA, but with an RSI of 36.8 and consensus upside of +16.6%, it doesn’t meet Veqtio’s strict BUY criteria for oversold conditions or significant upside potential.
| 📍 Entry Zone | $160 or below | 🛑 Stop-Loss | $150 |
| 📋 Adjust If | RSI drops below 30 or revenue growth accelerates above 10% YoY. | ||
💡 The Investment Case — Why Now?
Align Technology (ALGN) finds itself at a pivotal juncture. While the stock has seen a +7.3% return over the last three months, its recent -3.71% dip today and a -8.9% 1-month return highlight volatility. The company’s Q4 FY25 revenue of $1.0B, a +5.3% YoY increase, shows steady but not explosive growth, leading to a P/E multiple of 30.7x that demands strong future performance. Investors are weighing the long-term potential of clear aligners against current growth rates and valuation.
The primary risk to the investment thesis is a slowdown in consumer discretionary spending on elective dental procedures, which could directly impact Invisalign adoption rates. Additionally, increased competition in the clear aligner market from lower-cost alternatives could erode market share and pricing power, potentially impacting future revenue growth and profitability if not effectively countered by innovation and brand strength.
🏢 Company Overview
| Category | Detail |
|---|---|
| Company | Align Technology, Inc. |
| Ticker / Exchange | ALGN / NYSE / NASDAQ |
| Sector / Industry | Healthcare / Medical Instruments & Supplies |
Peer P/E Comparison
| Ticker | Name | P/E (TTM) |
|---|---|---|
| ALGN | (This stock) | 30.7x |
| S&P 500 Avg | S&P 500 Avg | 21.0x |
| UNH | UnitedHealth Group Incorporate | 20.8x |
| JNJ | Johnson & Johnson | 21.3x |
| LLY | Eli Lilly and Company | 39.5x |
| PFE | Pfizer, Inc. | 19.8x |
📊 Price Action & Technicals
$173.18
-8.9%
+7.3%
-16.86%
Neutral
ALGN’s current price of $173.18 is trading below its 50-day SMA ($176.25) but above its 200-day SMA ($159.78), indicating mixed short-term and long-term trends. The RSI at 36.8 suggests the stock is approaching oversold territory, while the MACD indicates a neutral momentum. The price is positioned at 35.3% within its Bollinger Bands, closer to the lower band, suggesting some downside pressure but not extreme oversold conditions yet.
📈 Earnings Deep Dive
| Period | Revenue | EPS | YoY |
|---|---|---|---|
| Q4 FY25 | $1.0B | N/A | +5.3% |
| Q3 FY25 | $996M | $0.78 | +1.8% |
| Q2 FY25 | $1.0B | $1.72 | -1.6% |
| Q1 FY25 | $979M | $1.27 | -1.8% |
🚀 Growth Drivers — What Moves the Stock
- Global Market Expansion: Align Technology continues to penetrate international markets, particularly in emerging economies, driving adoption of Invisalign. This geographic diversification is key to sustaining revenue growth. 🟢
- Product Innovation & Portfolio Expansion: Ongoing R&D into new clear aligner solutions, digital workflows, and complementary products like iTero scanners enhances their ecosystem, attracting more orthodontists and general practitioners. 🟡
- Increased Adult Orthodontic Demand: A growing trend of adults seeking orthodontic treatment, combined with the discreet nature of clear aligners, provides a significant and expanding addressable market for ALGN. 🟢
🧠 Smart Money & Institutional Positioning
Institutional Holdings (Top 5)
| Institution | Shares (K) |
|---|---|
| Vanguard Group Inc | 8,179 |
| Capital International In | 4,643 |
| Blackrock Inc. | 4,360 |
| State Street Corporation | 2,528 |
| Ninety One UK Ltd | 2,227 |
Holdings reflect most recent 13F (45-day lag). QoQ change not available.
Short Interest
| Metric | Value |
|---|---|
| Short % of Float | 4.31% |
| Days to Cover | 1.7 |
The low short interest of 4.31% and 1.7 Days to Cover indicates limited bearish conviction among short sellers.
⚠️ Key Risk Factors — Risk Matrix
Economic Slowdown Impact: Reduced consumer discretionary spending could directly lower demand for elective orthodontic procedures.
~$8B impact
Increased Competition: Growing competition from new clear aligner providers and traditional braces could pressure pricing and market share.
~$15B+ impact
Regulatory & Litigation Risks: Potential for new regulations or ongoing legal challenges related to patents or product claims could impact operations.
~$8B impact
Supply Chain Disruptions: Reliance on global supply chains for materials and manufacturing could lead to disruptions impacting production.
~$3B impact
🎯 Guidance & Wall Street View
Recent Analyst Actions
| Firm | Rating | Price Target | Date | Action |
|---|---|---|---|---|
| Barclays | Overweight | $200.00 | 2026-03-17 | Upgrade |
| HSBC | Buy | $200.00 | 2026-02-09 | Upgrade |
| Stifel | Buy | $210.00 | 2026-02-05 | Maintain |
| Piper Sandler | Overweight | $220.00 | 2026-02-05 | Maintain |
| UBS | Neutral | $185.00 | 2026-02-05 | Maintain |
Consensus Price Target Distribution
| High Target | Mean Target | Low Target | Total Analysts | Consensus Rating |
|---|---|---|---|---|
| $225 | $202 | $169 | 13 | BUY |
The analyst consensus points to a BUY rating, with a mean target of $202, suggesting a +16.6% upside from the current price. The target range from $169 to $225 indicates a moderate spread, reflecting varied outlooks on growth and market penetration.
⚖ Bull vs Bear — Probability-Weighted Scenarios
Bull Case: Strong Adoption & Innovation
- Accelerated global adoption of Invisalign, especially in untapped markets, coupled with successful new product launches.
- Effective management of competitive pressures, maintaining premium pricing and market leadership through brand strength and technological edge.
Implied Target: $225
Base Case: Steady Growth & Market Resilience
Align Technology continues its steady growth trajectory, driven by consistent Invisalign demand and incremental market expansion. While competition persists, ALGN maintains its dominant position, achieving analyst consensus targets.
Implied Target: $202
Bear Case: Market Saturation & Intense Competition
- Significant slowdown in market growth or increased price wars from competitors eroding profit margins and market share.
- Unfavorable regulatory changes or major product recalls impacting consumer trust and operational costs.
Implied Target: $169
Disclaimer & Hashtags
This Veqtio analysis is for informational and educational purposes only and does not constitute financial advice. Investors should conduct their own due diligence and consult with a qualified financial advisor before making any investment decisions. All data is sourced from publicly available information as of 2026-03-21.
All active positions and their real-time performance are tracked on our Investment Log.
#ALGN #AlignTechnology #USStocks #StockAnalysis #Veqtio #Healthcare #MedicalDevices #Orthodontics